Icon

TRIAMCINOLONE ACETONIDE (nda011600)- (0.025%,0.1%)

TRIAMCINOLONE ACETONIDE RISING
0.025%,0.1%
No No
Expired Expired
None None
None No
Triamcinolone Acetonide Ointment 0.025%, 0.1%, and 0.5% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
9 0 9
Total Other Developers 4
Drugs with Suitability Yes
0.025% ** ** - - 4
0.1% ** ** - - 6
NDA Sales Available Total Generic Sales Available
No 7
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ******* ** ******* *** ****, ***. *********** **** ******** ***, *****, *** **** (**) *****, ****** ****** (***) ***
****** ******* ** ******* ****** *************** *** *********** * ********* ***, *******, *******, ****** (***) ***
****** ******* ******* *************** ** ************, *** *********** **** ***** ****, **********, ***** ******** (**) *****, ****** ****** (***) ***
****** ******** ****** *** ****** **** *********** ******* *****, *.*. **********, ****** - *****, *****, ******** ******* ******, ***** (***) ***
****** **** **** *************** ***. *********** *** **** *****, ********, ******* *** ***, ****** (***) ***
****** ******* ******* *************** ** ************, *** *********** **** ***** ****, **********, ***** ******** (**) *****, ****** ****** (***) ***
****** ****** ****** ******** ******* ******* *********** **** ** *-* ******* ********** ******, *****, ******, ***** (***) ***
****** ********* ** ***** ************, ***. *********** *** ****** *****, ********, *** ****** (**) *****, ****** ****** (***) ***
****** ******** ****** ******** *************** ******* *********** ******* ********** ***** ******** ****, *****, *****, ******** ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.